MedTrace Logo

Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy

NCT00328874 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-01-10

No results posted yet for this study

Summary

Study hypothesis:

A 6-week p.o treatment with 5 mg/Kg Coenzyme Q10 is safe and tolerable,increases the brain's metabolism and ameliorates clinical symptoms in patients with PSP.

Conditions

Interventions

DRUG

Coenzyme Q10

Sponsors & Collaborators

  • MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany

    collaborator UNKNOWN

  • Pitzer Stiftung

    collaborator UNKNOWN

  • Philipps University Marburg

    collaborator OTHER

  • German Parkinson Study Group (GPS)

    lead OTHER

Principal Investigators

  • Wolfgang Oertel, Professor · Neurologische Klinik der Philipps Universität Marburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Completion
2007-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00328874 on ClinicalTrials.gov